AC Immune S.A.
ACIUNASDAQHealthcare● Active
$2.19
$-0.06(-2.67%)
Market Cap$222884125
P/E Ratio—
52W High$4
52W Low$1.65
AC Immune S.A. (ACIU) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACIU · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.19
Est. -$0.20 · +5.0%
Revenue
$0.00B
Est. $0.00B · +325.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
ACIU reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.25 | — | — | — | $0.05B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$0.20 | -$0.19 | +5.0% | $0.00B | $0.00B | +325.0% |
| ▲ Q1 FY2026 | Mar 13, 2026 | -$0.19 | -$0.18 | +5.3% | $0.00B | $0.00B | -70.3% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.22 | -$0.20 | +9.1% | $0.00B | $0.00B | +3.2% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.20 | -$0.25 | -25.0% | $0.00B | $0.00B | +420.5% |
| ▲ Q2 FY2025 | Apr 30, 2025 | -$0.22 | -$0.21 | +4.5% | $0.00B | $0.00B | +145.4% |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.21 | -$0.18 | +14.3% | $0.00B | $0.00B | +52.8% |
| ▲ Q4 FY2024 | Nov 5, 2024 | -$0.20 | $0.05 | +125.0% | $0.03B | $0.00B | +2036.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.20
EPS Surpr.
+5.0%
Revenue
$0.00B
Q1 FY2026
Mar 13, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.3%
Revenue
$0.00B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.22
EPS Surpr.
+9.1%
Revenue
$0.00B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.20
EPS Surpr.
-25.0%
Revenue
$0.00B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.22
EPS Surpr.
+4.5%
Revenue
$0.00B
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.21
EPS Surpr.
+14.3%
Revenue
$0.00B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.05
EPS Est.
-$0.20
EPS Surpr.
+125.0%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q3 FY2026 | $-0.18 | $-0.16 | $-0.14 | 2 |
| Q2 FY2026 | $0.18 | $0.20 | $0.22 | 1 |
| Q1 FY2026 | $-0.17 | $-0.15 | $-0.14 | 1 |
| Q4 FY2025 | $-0.18 | $-0.17 | $-0.15 | 2 |
| Q3 FY2025 | $-0.19 | $-0.18 | $-0.17 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +5.0% | $2.93 | $3.03 | +3.41% |
| ▲ Q1 FY2026 | Mar 13, 2026 | +5.3% | $3.00 | $3.02 | +0.67% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +9.1% | $3.18 | $3.30 | +3.77% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -25.0% | $2.19 | $2.45 | +11.87% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +4.5% | $1.70 | $1.73 | +1.76% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +14.3% | $2.32 | $2.30 | -0.86% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +125.0% | $2.94 | $3.24 | +10.20% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -159.5% | $3.49 | $3.53 | +1.15% |
Q2 FY2026+3.41%
Report Date
Apr 30, 2026
EPS Beat/Miss
+5.0%
Price Before
$2.93
Price After
$3.03
Q1 FY2026+0.67%
Report Date
Mar 13, 2026
EPS Beat/Miss
+5.3%
Price Before
$3.00
Price After
$3.02
Q4 FY2025+3.77%
Report Date
Nov 4, 2025
EPS Beat/Miss
+9.1%
Price Before
$3.18
Price After
$3.30
Q3 FY2025+11.87%
Report Date
Aug 5, 2025
EPS Beat/Miss
-25.0%
Price Before
$2.19
Price After
$2.45
Q2 FY2025+1.76%
Report Date
Apr 30, 2025
EPS Beat/Miss
+4.5%
Price Before
$1.70
Price After
$1.73
Q1 FY2025-0.86%
Report Date
Mar 13, 2025
EPS Beat/Miss
+14.3%
Price Before
$2.32
Price After
$2.30
Q4 FY2024+10.20%
Report Date
Nov 5, 2024
EPS Beat/Miss
+125.0%
Price Before
$2.94
Price After
$3.24
Q3 FY2024+1.15%
Report Date
Aug 6, 2024
EPS Beat/Miss
-159.5%
Price Before
$3.49
Price After
$3.53
Avg Beat Reaction+3.16%
Avg Miss Reaction+6.51%
Beat Rate6 / 8 quarters
Largest Move+11.87% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACIU ends December
AC Immune S.A. (ACIU) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.20 by +5.0%. ACIU has beaten EPS estimates for 3 consecutive quarters. The next ACIU earnings date is expected around September 1, 2026.
Each quarter, investors track ACIU earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACIU revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACIU's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACIU earnings · 5 questionsAC Immune S.A.'s next earnings report is expected around September 1, 2026. ACIU typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACIU historically reports after market close (AMC).
ACIU earnings datewhen is ACIU earningsACIU next earnings datewhen does ACIU report earningsACIU earnings calendar
▸ Source: FMP · AC Immune S.A. SEC filings · US GAAP · AC Immune S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026